| Project/Area Number |
17590909
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Tokyo Metropolitan Organization for Medical Research |
|---|
Principal Investigator |
OKURA Yoshio Tokyo Metropolitan Organization for Medical Research, Researcher, 東京都神経科学総合研究所, 研究員 (10392367)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUMOTO Yoh Tokyo Metropolitan Organization for Medical Research, Researcher, 東京都神経科学総合研究所, 参事研究員 (90173921)
KOHYAMA Kuniko Tokyo Metropolitan Organization for Medical Research, Researcher, 東京都神経科学総合研究所, 研究員 (80301795)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Alzheimer's disease / therapy / DNA vaccine / Aベータ |
|---|
| Research Abstract |
It was recently demonstrated that amyloid beta (Aβ) peptide vaccination was effective in reducing Aβ burden in Alzheimer model mice. However, the clinical trial was halted due to the development of meningoencephalitis in some patients. To overcome this problem, anti-Aβ antibody therapy and other types of vaccination are now in trial. In the present study, we have developed safe and effective non-viral Aβ DNA vaccines against Alzheimer's disease. We administered these vaccines to model mice (APP23 mice) and evaluated Aβ burden reduction. Prophylactic treatments started before Aβ deposition reduced Aβ burden to 15.5% and 38.5% of that found in untreated mice at 7 and 18 months of age, respectively. Therapeutic treatment started after Aβ deposition reduced Aβ burden to approximately 50% at age of 18 months. Importantly, this therapy induced neither neuroinflammation nor T cell responses to Aβ peptide in both APP23 and wild type B6 mice even after long-term vaccination. While it is reported that other anti-Aβ therapies have pharmacological and/or technical difficulties, non-viral DNA vaccines are highly secure and easily controllable and are promising for the treatment of Alzheimer's disease.
|
